Ignite Creation Date:
2025-12-24 @ 3:03 PM
Ignite Modification Date:
2026-05-13 @ 2:02 PM
Study NCT ID:
NCT02855359
Status:
TERMINATED
Last Update Posted:
2019-03-11
First Post:
2016-07-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Sponsor:
Seagen Inc.
Organization:
Conditions & Keywords Data
Conditions:
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Antibodies, Monoclonal | View |
| None | SGN-19A | View |
| None | Denintuzumab Mafodotin | View |
| None | DLBCL | View |
| None | Antibody-Drug Conjugate | View |
| None | Antigens, CD19 | View |
| None | Hematologic Diseases | View |
| None | Immune System Diseases | View |
| None | Immunoproliferative Disorders | View |
| None | Immunotherapy | View |
| None | Lymphatic Diseases | View |
| None | Lymphoma | View |
| None | Lymphoma, B-Cell | View |
| None | Lymphoma, Large B-Cell, Diffuse | View |
| None | Lymphoma, Non-Hodgkin | View |
| None | Monomethyl auristatin F | View |
| None | Neoplasms | View |
| None | Neoplasms by Histologic Type | View |
| None | Transformed Lymphoma / DLBCL | View |
| None | Cyclophosphamide | View |
| None | Doxorubicin | View |
| None | Liposomal doxorubicin | View |
| None | Prednisone | View |
| None | Rituximab | View |
| None | Vincristine | View |
| None | Alkylating Agents | View |
| None | Anti-Inflammatory Agents | View |
| None | Antibiotic, Antineoplastic | View |
| None | Antimitotic Agents | View |
| None | Antineoplastic Agents, Alkylating | View |
| None | Antineoplastic Agents | View |
| None | Phytogenic Antirheumatic Agents | View |
| None | Glucocorticoids | View |
| None | Drug Therapy | View |
| None | Follicular Lymphoma Grade 3b | View |
| None | immunosuppressive agents | View |